Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04LLK
|
|||
| Drug Name |
Chloroacetyl ester derivative 1
|
|||
| Synonyms |
PMID26560530-Compound-10
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
N Zyme Biotech GmbH
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H17ClN2O7
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)COC(=O)NC(COC(=O)CCl)C(=O)NCC(=O)O
|
|||
| InChI |
1S/C15H17ClN2O7/c16-6-13(21)24-9-11(14(22)17-7-12(19)20)18-15(23)25-8-10-4-2-1-3-5-10/h1-5,11H,6-9H2,(H,17,22)(H,18,23)(H,19,20)/t11-/m0/s1
|
|||
| InChIKey |
UEILGHHGUUQOCS-NSHDSACASA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.